GM-CSF Promotes the Immunosuppressive Activity of Glioma-infiltrating Myeloid Cells Through Interleukin-4 Receptor-α
Overview
Authors
Affiliations
Malignant gliomas are lethal cancers in the brain and heavily infiltrated by myeloid cells. Interleukin-4 receptor-α (IL-4Rα) mediates the immunosuppressive functions of myeloid cells, and polymorphisms in the IL-4Rα gene are associated with altered glioma risk and prognosis. In this study, we sought to evaluate a hypothesized causal role for IL-4Rα and myeloid suppressor cells in glioma development. In both mouse de novo gliomas and human glioblastoma cases, IL-4Rα was upregulated on glioma-infiltrating myeloid cells but not in the periphery or in normal brain. Mice genetically deficient for IL-4Rα exhibited a slower growth of glioma associated with reduced production in the glioma microenvironment of arginase, a marker of myeloid suppressor cells, which is critical for their T-cell inhibitory function. Supporting this result, investigations using bone marrow-derived myeloid cells showed that IL-4Rα mediates IL-13-induced production of arginase. Furthermore, glioma-derived myeloid cells suppressed T-cell proliferation in an IL-4Rα-dependent manner, consistent with their identification as myeloid-derived suppressor cells (MDSC). Granulocyte macrophage colony-stimulating factor (GM-CSF) plays a central role for the induction of IL-4Rα expression on myeloid cells, and we found that GM-CSF is upregulated in both human and mouse glioma microenvironments compared with normal brain or peripheral blood samples. Together, our findings establish a GM-CSF-induced mechanism of immunosuppression in the glioma microenvironment via upregulation of IL-4Rα on MDSCs.
Ivanov S, Lagunin A, Tarasova O Comput Struct Biotechnol J. 2025; 23:3559-3574.
PMID: 39963421 PMC: 11832006. DOI: 10.1016/j.csbj.2024.09.022.
Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.
Asioli S, Gatto L, Vardy U, Agostinelli C, Di Nunno V, Righi S Cancers (Basel). 2024; 16(22).
PMID: 39594814 PMC: 11592556. DOI: 10.3390/cancers16223859.
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment.
Hanahan D, Michielin O, Pittet M Nat Rev Cancer. 2024; 25(1):41-58.
PMID: 39448877 DOI: 10.1038/s41568-024-00761-z.
Locoregional therapies combined with immune checkpoint inhibitors for liver metastases.
Zhang X, Zhou Y, Wei G, Luo Y, Qiu M Cancer Cell Int. 2024; 24(1):302.
PMID: 39217341 PMC: 11365172. DOI: 10.1186/s12935-024-03484-1.
Du L, Zhang Q, Li Y, Li T, Deng Q, Jia Y Front Oncol. 2024; 14:1409519.
PMID: 39206155 PMC: 11349564. DOI: 10.3389/fonc.2024.1409519.